GALXC PLUS

WIPO WIPO 2021

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark GALXC PLUS was filed as Word mark on 07/14/2021 at the World Intellectual Property Organization.

Trademark Details Last update: April 7, 2023

Trademark form Word mark
File reference 1610784
Countries Australia Canada China em United Kingdom Japan
Base trademark US No. 90458999, January 11, 2021
Application date July 14, 2021
Expiration date July 14, 2031

Trademark owner

87 Cambridgepark Drive
Cambridge MA 02140
US

Trademark representatives

Two Commerce Square, 2001 Market Street, US

goods and services

05 Oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide delivery agents for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; oligonucleotide compounds for use in the targeted delivery of RNAi therapy; oligonucleotide delivery agents consisting of compounds that facilitate the delivery of a wide range of pharmaceutical and therapeutic agents intravenously or subcutaneously for use in targeted pharmaceutical therapies for a wide range of medical purposes; drug delivery agents consisting of oligonucleotide compounds that facilitate the delivery of a wide range of pharmaceutical based therapies
42 Research and development of oligonucleotide compounds for use in targeted pharmaceutical therapies for the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections; research and development of pharmaceutical preparations for the treatment of disorders outside the liver; research and development of oligonucleotide compounds for targeted gene silencing; research and development of oligonucleotide drug delivery platforms for use in the treatment of rare diseases, genetic disorders, cardiovascular diseases, and viral infections

Trademark history

Date Document number Area Entry
April 5, 2023 2023/14 Gaz CA Rejection
December 22, 2022 2022/52 Gaz JP RAW: Rule 18ter(2)(ii) GP following a provisional refusal
June 2, 2022 2022/22 Gaz JP Rejection
February 23, 2022 2022/8 Gaz AU Rejection
January 19, 2022 2022/3 Gaz EM Rejection
January 5, 2022 2022/1 Gaz GB Rejection
January 5, 2022 2022/2 Gaz CN Rejection
July 14, 2021 2021/33 Gaz US Registration

ID: 141610784